Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Reviews
Search Article 
  
Advanced search 
 


 
 Table of Contents  
PLANT REVIEW
Year : 2016  |  Volume : 10  |  Issue : 20  |  Page : 109-114  

An updated review on the phytochemistry, pharmacology, and clinical trials of Salacia oblonga


1 Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India
2 Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India

Date of Web Publication14-Nov-2016

Correspondence Address:
Sudipta Saha
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Rai Bareli Road, Lucknow - 226 025, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-7847.194046

Rights and Permissions
   Abstract 


Salacia oblonga (S. oblonga), a perennial herb, has been used for thousands of years in ayurvedic medicine and is closely associated with prevention, treatment, and cure of various human ailments such as obesity and diabetes. A vast and wide range of chemical compounds such as polyphenols, friedelane-type triterpenes, norfriedelane-type triterpenes, eudesmane-type sesquiterpenes including various glycosides had been isolated from this plant. This review is aimed to survey the literature covering the phytochemistry and pharmacology of S. oblonga and to review the scientific data including active components and their multi-targeted mechanisms of action against various metabolic syndromes. We also included clinical trials related to this plant in this review. The overview would assist researchers to gather scientific information related to S. oblonga in future.

Keywords: Clinical trials, pharmacology, phytochemistry, Salacia oblonga


How to cite this article:
Kushwaha PS, Singh AK, Keshari AK, Maity S, Saha S. An updated review on the phytochemistry, pharmacology, and clinical trials of Salacia oblonga. Phcog Rev 2016;10:109-14

How to cite this URL:
Kushwaha PS, Singh AK, Keshari AK, Maity S, Saha S. An updated review on the phytochemistry, pharmacology, and clinical trials of Salacia oblonga. Phcog Rev [serial online] 2016 [cited 2017 Oct 19];10:109-14. Available from: http://www.phcogrev.com/text.asp?2016/10/20/109/194046




   Introduction Top


In the search for novel therapeutic molecules, the hybrid approach is to target multi-factorial diseases, especially metabolic syndrome. Natural products have been recognized as one of the major sources of hybrid molecules containing multi-structural units of a different class.[1] Continuous finding is necessary to find out multi-targeted therapeutics, which is helpful for newer drug discovery. To hit them, two strategies are adopted during discovery. Single compound is used to hit multiple targets which is the first approach and the second is to employ two or more active ingredients in a single drug.[2]

Salacia oblonga, commonly known as ''ponkoranti'' (Family: Celastraceae), due to its golden color root bark,[3] has been emerged to act as an active ingredient to hit multiple targets, preferably in case of all diabetic complications such as impaired glucose uptake, insulin resistance, dyslipidemia, cardiac complications, kidney disorder by acting through multiple targets either by the inhibition of α-glucosidase, aldose reductase (AR), pancreatic lipase, or by the activation of glucose transporter-4 (GLUT-4)-mediated glucose uptake, and various peroxisome proliferator-activated receptor (PPAR) subtypes.[4],[5],[6],[7],[8]

A plethora of research data indicates that numerous bioactive components from S. oblonga are potentially useful in the treatments of obesity, diabetes, and its complications. Several reports have described the hypoglycemic activity of S. oblonga in animals.[9],[10] Furthermore, clinical trial had been performed using S. oblonga herbal preparation.[11],[12],[13],[14] Again, no adverse effect was reported with S. oblonga extract (SOE) in rats, which supports a good safety potential in human.[15],[16]

To date, despite the wealth of information available on the therapeutic importance of S. oblonga in literature, no review summarizes the real update on the molecular basis of biological activities and mechanisms of action of its active compound. Therefore, we surveyed research papers and clinical trials on S. oblonga and reviewed the scientific data, including active components and pharmacology. This review will provide the researchers with the current status of S. oblonga with a special emphasis on the regulation of hybrid approach of multiple molecular targets and their mechanism of action in diabetes, obesity, and their consequent complications, including various toxicological and cytogenetic aspects.

Phytochemistry

The phytoconstituents of S. oblonga are numerous, and they vary depending on the species to species and place of origin.[17] Kotalanol, kotalagenin 16-acetate, and salacinol were found in the root of S. oblonga.[7]S. oblonga hot water extract of root contains 1.4% of mangiferin (MA),[6] which was identified and quantified by high-performance liquid chromatography method. Apart from these unique constituents, the extract of S. oblonga has also been reported to contain neokotalanol,[18] ponkoranol,[19] neosalacinol, neoponkoranol,[18] 26-hydroxy-1,3-friedelanedione, 3 β,22α-dihydroxyolean-12-en-29-oic acid,[20] (-)-4-O-methylepigallocatechin,[21] salasol A,[22] salasol B, salasones A, salasones B, salasones C, salasones D, salasones E, salaquinone A, salaquinone B,[22],[23] and 25,26-oxidofriedelane-1,3-dione.[24] All the chemical components of S. oblonga with their chemical structures are given in [Figure 1].
Figure 1: Important phytochemicals of S. oblonga participating in biological activities

Click here to view


Pharmacological Uses

The extract of S. oblonga has diverse local and traditional uses because of its action on different molecular targets in the human body. Herein, the different chemical constituents of the extract act on the different molecular targets owing to several useful biological activities which are summarized in [Table 1].
Table 1: Multi-targeted approach of biological activities

Click here to view


Diabetes

Inhibition of α-glucosidase

Oxidative stress has an important contribution during diabetes propagation.[25] Numerous reports have documented that the reduction of antioxidant defenses is observed during an oral glucose challenge.[26],[27] Glucose absorption delays during the inhibition of metabolic enzymes which suppresses postprandial hyperglycemia, resulting in improved glycemic control [Figure 2].[12]S. oblonga root (SOR) extract lowered glucose and increased insulin levels in patients with type 2 diabetes after meal.[28] The production of salacinol, kotalanol and kotalagenin-16-acetate maltose, sucrose, or starch was strong in rat plasma.[6],[7],[29],[30]
Figure 2: Function of intestinal α-glucosidase enzyme (positive circled sign shows activation and negative circled sign shows inhibition)

Click here to view


In another experiment,[6] water extract of SOR containing MA was investigated against type 2 diabetes during cardiac fibrosis using obese Zucker rats, and the researchers demonstrated that SOR extract restored blood glucose level during cardiac fibrosis. It has also been demonstrated that MA showed much weaker effects than that of SOE having salacinol and kotalanol, suggesting that MA is a moderately active constituent for inhibiting α-glucosidase enzyme.[6]

Activation of glucose transporter 4-mediated glucose uptake

S. oblonga produced GLUT-4 activation through the inhibition of intestinal α-glycosidases and augmentation of glucose uptake in muscle and adipose tissues. Mangifrerin is the key constituent of SOE, which enhances 2-deoxy-D-glucose uptake by 50% in both L6-myotubes and 3T3-adipocytes. In addition, the effects are most likely mediated through two individual pathways that are linked to protein kinase and PPAR-γ activation.[4]

Inhibition of aldose reductase

Kotalagenin-16-acetate and MA had a dramatic role in AR inhibition which was observed in rats' lens-derived AR.[7],[8] In another study, MA is reported to possess the onset or progression of diabetic complications including diabetic neuropathy and nephropathy.[31] These results further coined the protective effect of S. oblonga on vascular and other complications of diabetes.

Inhibition of nicotinamide adenine dinucleotide phosphate oxidase enzyme

During specified application,[32]S. oblonga demonstrated beneficial effects on mitochondrial localization in cells and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in glucose-induced rat muscle cell line. In this study, the L6 cells were treated with high glucose in the absence or presence of SOE, and the NADPH oxidase enzyme activity was determined in cell lysates of control and treated groups.[33] NADPH oxidase enzyme activity was measured in terms of percentage of NADPH consumed in comparison to control. The data from this investigation suggested that high glucose concentration increased the oxidative stress in rat skeletal muscle cell line through the production of increasing amount of superoxide radicals by NADPH oxidase enzyme. Altogether, the study proved the antioxidant potential of SOE and indicated the possible involvement of skeletal muscle mitochondria in helping cells survive the stress.[32]

Inhibition of pancreatic lipase

SOE reduced plasma triglyceride level after loading olive oil in Zucker diabetic fatty (ZDF) rats, whereas it had no effect on plasma triglyceride in the fasted rats.[34] These results suggested that S. oblonga inhibited olive oil-induced hypertriglyceridemia by targeting the gastrointestinal system. The hot water extract of S. oblonga suppressed pancreatic lipase activity.[20] Therefore, the inhibition of pancreatic lipase activity in the small intestine was suggested as one of the main mechanisms of improvement of postprandial hyperlipidemia in type 2 diabetes and obesity by Salacia root.

Peroxisome proliferator-activated receptor-γ activator

PPAR-γ is a transcription factor predominantly expressed in adipose tissue, and it activates adipocyte differentiation both in vivo and in vitro.[35] When PPAR-γ is overexpressed, 3T3-L1 preadipocyte induction begins. This suggests that PPAR-γ suppression blocks adipogenesis and lipogenesis.[36] Thus, PPAR-γ agonism leads to the amelioration of lipid abnormalities in dyslipidemic patients. Findings from a number of rodent studies have demonstrated that PPAR-γ agonists can improve insulin resistance, as well as dyslipidemia. Concomitantly, rodent disease models have demonstrated that PPAR-γ agonists prevented increased adiposity and body weight without any reduction in food intake.[37] An experiment showed that MA increases 2-deoxy-D-glucose uptake in both L6-myotubes and 3T3-adipocytes, and the effects are most likely to be mediated via two pathways, related to 5'-AMP-activated protein kinase and PPAR-γ and may be blocked by GW9662, an irreversible PPAR-γ antagonist.[4]Salacia species are also reported to inhibit PPAR-γ-mediated gene expression in 3T3-L1adipocytes.[38]

Activation of insulin-mediated signaling

Type 2 diabetes mellitus is a complex disorder in which the interaction between environmental and genetic factors results in the development of insulin resistance in peripheral tissues and β-cell dysfunction.[39],[40] Among the various natural compounds, pentacyclic triterpenoids present in S. oblonga are a class of pharmacologically active and structurally rich metabolites with privileged motifs for further modifications, which are reported to act on glucose metabolism. Thus, it has become clear that PTs may exert their glucose-lowering effect through multi-target pathways, and these molecular targets include glycogen protein kinase B, protein tyrosine phosphatase 1B, insulin receptor, glucocorticoid receptor, phosphorylase, and the membrane G protein-coupled receptor (TGR5).[41] Therefore, oleane-, ursane-, and lupane-type triterpenes have been extensively studied.[42],[43],[44],[45]

Cardioprotective action

Huang et al. found that SOE-treated ZDF rats showed less cardiac hypertrophy. SOE is used to suppress cardiac overexpression of atrial natriuretic peptide (ANP), brain natriuretic peptide, AT1 mRNAs, and angiotensin-1 (AT1) protein in ZDF rats. While SOE and MA suppressed angiotensin-II-induced ANP mRNA overexpression and protein synthesis in H9c2 cells. Their findings demonstrated that SOE decreases cardiac hypertrophy in ZDF rats, at least in part by inhibiting AT1 overexpression.[46]

Huang et al. suggested that SOE diminished cardiac hypertrophy by decreasing the excessive collagen accumulation and the enlargement of cardiomyocytes. Besides, AT1 also mediates the autocrine and paracrine effects of locally formed angiotensin-II which are believed to play a key role in the development of cardiac hypertrophy.[47] Furthermore, SOE also suppressed angiotensin-II-stimulated hypertrophic response and protein synthesis in heart-derived H9c2 cells and angiotensin-II-accelerated hyperplasia in rat cardiac fibroblasts.[5] Altogether, these findings suggest that at least a part of the anti-hypertrophic and anti-fibrogenic effects of SOE occur via a cardiac angiotensin-II type 1 receptor/AT1 pathway.

Anti-inflammatory activity

SOE had been shown to exhibit anti-inflammatory response by inhibiting the release of mediators of inflammation and or the stabilization of lysosomes. Recent studies demonstrated that an anti-inflammatory characteristic of SOEwas observed on carrageenan and cotton plate-induced rat paw edema at the doses of 500, 1000, 1500, and 2000 mg/kg. The extract at 1000 mg/kg decreased the paw edema volume by 74.19% within 1 h after administration, while the standard drug hydrocortisone decreased the paw edema volume by 68.21% with respect to control.[48],[49]

Anti-microbial activity

SOE was effective against Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Bacillus subtilis, and Listeria monocytogenes) and Gram-negative bacteria (Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, Pseudomonas aeruginosa, Escherichia coli, and Salmonella typhimurium) and fungus (Aspergillus niger). S. oblonga exhibited the highest activity against K. pneumonia than ethyl acetate extract in acidic media than neutral media. It is also used in the treatment of various bacterial infectious diseases such as gonorrhea, rheumatism, and skin diseases.[50]

Nephroprotective activity

Ethanol extracts of S. oblonga demonstrated protective activity against paracetamol-induced renal injury. The extract increased the level of anti-oxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase, and restored glutathione levels than paracetamol control groups.[51]

Anti-mutagenic activity

The hydroalcholic extract of root bark of S. oblonga had anti-mutagenic activity against mitomycin-C-induced testicular toxicity in albino Wistar rats. The measured parameters were sperm shape abnormality, sperm count, catalase, superoxide dismutase, and total protein. The results suggested that sperm shape abnormality and sperm count were restored to normal level at 1 g/kg of dose of extract. The enzyme levels also increased during the experiment, and the total protein level was similar to normal control.[52]

Weight loss

S. oblonga promoted weight loss via increasing the activities of cholecystokinin and glucagon-like peptide-1 at 1000 mg dose for 30 days. It also reduced the absorption of glucose by inhibiting the activity of oligonucleotides.[53]


   Clinical Trials Top


The effects of SOE on postprandial glycemia and insulinemia were studied recently in 66 patients with type 2 diabetes in a randomized, double-blinded, crossover controlled trial. Each patient was administered with one of the three meals: A standard liquid control meal, a control meal + 240 mg SOE, and a control meal + 480 mg SOE. Both of the doses containing Salacia extract were found to be beneficial to this population for postprandial glucose control.[28]

The presence of SOE tends to lower postprandial glycemia and significantly reduce the postprandial insulin response. This result has been shown through repeated measurements of the effect of different doses of SOE on postprandial glycemic, insulinemic, and breath hydrogen responses in healthy adults through a double-masked, randomized, crossover design in 39 healthy, nondiabetic adults.[12]

Another clinical trial on a proprietary formulation Glucaffect™ was performed on 50 overweight patients in a single-blinded fashion. The rationale of the study was to prolong the satiety of overweight volunteers by providing delayed absorption of carbohydrates. Glucaffect™ provides potent α-glucosidase inhibitors of herbal sources such as French maritime pine bark extract Pycnogenol ®, Syzygium cumini Madeglucyl™, and SOE. Consumption of Glucaffect™ enabled patients to lower blood-fasting glucose, body weight, and HbA1c levels as compared to the control group.[59]

In another randomized, double-masked, crossover design, 43 healthy controls were fed with one of the four meals: Control (a study beverage containing carbohydrate, protein, and fat), control + phenylalanine and leucine (AA), control + SOE, and control + SOE and AA. This clinical trial manifested the extract of S. oblonga as a promising nutraceutical ingredient for glycemic control, and supplementation with amino acids had no significant additional effect on glycemia.[11]


   Conclusion Top


Prolonged exposure to high glucose concentration promotes the development of microvascular complications associated with diabetes mellitus. Such complications affect the kidneys (nephropathy), eyes (retinopathy), heart (cardiomyopathy), nerves (neuropathy), and blood vessels. Majority of the plants, except S. oblonga, used traditionally to cure diabetes have not been effective for the treatment of all diabetic complications. S. oblonga containing various active metabolites have been found to meet multiple targets to cure diabetes, obesity, and heart disease via inhibiting α-glucosidase, pancreatic lipase and AR, and modulating PPAR-α/γ-mediated lipogenic gene transcription, AT1 signaling, and GLUT-4-mediated glucose uptake. Although the multiple target regulatory activities of this unique ayurvedic medicine have been clearly shown to be of benefit, clinical trials are now crucial to evaluate the effectiveness and safety of S. oblonga in the treatment and prevention of these metabolic diseases in humans. In addition, further mechanistic studies are necessary to allow a better understanding of how the use of S. oblonga may interact with other therapeutic interventions. For the same reason, recently, there has been some excitement over the potential role of SOE.

Acknowledgement

We would like to acknowledge the funding support from the University Grants Commission for providing the Major Research Project to Dr. Sudipta Saha (Project No. 42-680/2013[SR]).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Decker M. Hybrid molecules incorporating natural products: Applications in cancer therapy, neurodegenerative disorders and beyond. Curr Med Chem 2011;18:1464-75.  Back to cited text no. 1
    
2.
Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-51.  Back to cited text no. 2
    
3.
Flammang AM, Erexson GL, Mecchi MS, Murli H. Genotoxicity testing of a Salacia oblonga extract. Food Chem Toxicol 2006;44:1868-74.  Back to cited text no. 3
    
4.
Girón MD, Sevillano N, Salto R, Haidour A, Manzano M, Jiménez ML, et al. Salacia oblonga extract increases glucose transporter 4-mediated glucose uptake in L6 rat myotubes: Role of mangiferin. Clin Nutr 2009;28:565-74.  Back to cited text no. 4
    
5.
Huang TH, He L, Qin Q, Yang Q, Peng G, Harada M, et al. Modulation of cardiac angiotensin II type 1 receptor signaling in Salacia oblonga-induced regression of cardiac hypertrophy in Zucker diabetic fatty rats. Diabetes Obes Metab 2007; [E-publication ahead of print].  Back to cited text no. 5
    
6.
Li Y, Peng G, Li Q, Wen S, Huang TH, Roufogalis BD, et al. Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese Zucker rats. Life Sci 2004;75:1735-46.  Back to cited text no. 6
    
7.
Matsuda H, Murakami T, Yashiro K, Yamahara J, Yoshikawa M. Antidiabetic principles of natural medicines. IV. Aldose reductase and qlpha-glucosidase inhibitors from the roots of Salacia oblonga Wall. (Celastraceae): Structure of a new friedelane-type triterpene, kotalagenin 16-acetate. Chem Pharm Bull (Tokyo) 1999;47:1725-9.  Back to cited text no. 7
    
8.
Yoshikawa M, Nishida N, Shimoda H, Takada M, Kawahara Y, Matsuda H. Polyphenol constituents from Salacia species: Quantitative analysis of mangiferin with alpha-glucosidase and aldose reductase inhibitory activities. Yakugaku Zasshi 2001;121:371-8.  Back to cited text no. 8
    
9.
Augusti KT, Joseph P, Babu TD. Biologically active principles isolated from Salacia oblonga Wall. Indian J Physiol Pharmacol 1995;39:415-7.  Back to cited text no. 9
    
10.
Krishnakumar K, Augusti KT, Vijayammal PL. Hypoglycaemic and anti-oxidant activity of Salacia oblonga Wall. extract in streptozotocin-induced diabetic rats. Indian J Physiol Pharmacol 1999;43:510-4.  Back to cited text no. 10
    
11.
Collene AL, Hertzler SR, Williams JA, Wolf BW. Effects of a nutritional supplement containing Salacia oblonga extract and insulinogenic amino acids on postprandial glycemia, insulinemia, and breath hydrogen responses in healthy adults. Nutrition 2005;21:848-54.  Back to cited text no. 11
    
12.
Heacock PM, Hertzler SR, Williams JA, Wolf BW. Effects of a medical food containing an herbal alpha-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults. J Am Diet Assoc 2005;105:65-71.  Back to cited text no. 12
    
13.
Jayawardena MH, de Alwis NM, Hettigoda V, Fernando DJ. A double blind randomised placebo controlled cross over study of a herbal preparation containing Salacia reticulata in the treatment of type 2 diabetes. J Ethnopharmacol 2005;97:215-8.  Back to cited text no. 13
    
14.
Kajimoto O, Kawamuri S, Shimoda H, Kawahara Y, Hirata H, Takahashi T. Effects of diet containing Salacia reticulata on mild type 2 diabetes in humans – A placebo controlled, cross over trial. J Jpn Soc Food Sci Technol 2000;53:199-205.  Back to cited text no. 14
    
15.
Flammang AM, Erexson GL, Mirwald JM, Henwood SM. Toxicological and cytogenetic assessment of a Salacia oblonga extract in a rat subchronic study. Food Chem Toxicol 2007;45:1954-62.  Back to cited text no. 15
    
16.
Rong X, Kim MS, Su N, Wen S, Matsuo Y, Yamahara J, et al. An aqueous extract of Salacia oblonga root, a herb-derived peroxisome proliferator-activated receptor-alpha activator, by oral gavage over 28 days induces gender-dependent hepatic hypertrophy in rats. Food Chem Toxicol 2008;46:2165-72.  Back to cited text no. 16
    
17.
Arunakumara KK, Subasinghe S. Salacia reticulata wight: A review of botany, phytochemistry and pharmacology. Trop Agric Res Ext 2010;13:41-7.  Back to cited text no. 17
    
18.
Yoshikawa M, Ninomiya K, Shimoda H, Nishida N, Matsuda H. Hepatoprotective and antioxidative properties of Salacia reticulata: Preventive effects of phenolic constituents on CCl4-induced liver injury in mice. Biol Pharm Bull 2002;25:72-6.  Back to cited text no. 18
    
19.
Tanabe G, Xie W, Ogawa A, Cao C, Minematsu T, Yoshikawa M, et al. Facile synthesis of de-O-sulfated salacinols: Revision of the structure of neosalacinol, a potent alpha-glucosidase inhibitor. Bioorg Med Chem Lett 2009;19:2195-8.  Back to cited text no. 19
    
20.
Yoshikawa M, Shimoda H, Nishida N, Takada M, Matsuda H. Salacia reticulata and its polyphenolic constituents with lipase inhibitory and lipolytic activities have mild antiobesity effects in rats. J Nutr 2002;132:1819-24.  Back to cited text no. 20
    
21.
Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives. Phytochemistry 2006;67:1849-55.  Back to cited text no. 21
    
22.
Morikawa T, Kishi A, Pongpiriyadacha Y, Matsuda H, Yoshikawa M. Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod 2003;66:1191-6.  Back to cited text no. 22
    
23.
Matsuda H, Yoshikawa M, Morikawa T, Tanabe G, Muraoka O. Antidiabetogenic constituents from Salacia species (Chemical and Pharmacological study). J Tradit Med 2005;22:145-53.  Back to cited text no. 23
    
24.
Anu SJ, Rao JM. New norfriedelene-1,-3dione from the root bark of Salacia oblonga. Chem Inform 2003;34: [DOI: 10.1002/chin.200335150].  Back to cited text no. 24
    
25.
Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.  Back to cited text no. 25
    
26.
Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 1998;28:329-33.  Back to cited text no. 26
    
27.
Tessier D, Khalil A, Fulop T. Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. J Gerontol 1999;54:M541-5.  Back to cited text no. 27
    
28.
Williams JA, Choe YS, Noss MJ, Baumgartner CJ, Mustad VA. Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes. Am J Clin Nutr 2007;86:124-30.  Back to cited text no. 28
    
29.
Wolf BW, Weisbrode SE. Safety evaluation of an extract from Salacia oblonga. Food Chem Toxicol 2003;41:867-74.  Back to cited text no. 29
    
30.
Matsuda H, Morikawa T, Yoshikawa M. Antidiabetogenic constituents from several natural medicines. Pure Appl Chem 2002;74:1301-8.  Back to cited text no. 30
    
31.
Faizal P, Suresh S, Satheesh Kumar R, Augusti KT. A study on the hypoglycemic and hypolipidemic effects of an ayurvedic drug Rajanyamalakadi in diabetic patients. Indian J Clin Biochem 2009;24:82-7.  Back to cited text no. 31
    
32.
Basu S, Pant M, Rachana SS. Beneficial effects of Salacia oblonga on mitochondrial localization in cells and NADPH oxidase activity in glucose induced cytotoxicity on rat muscle cell line. Int J Biotechnol Bioeng Res 2013;4:321-8.  Back to cited text no. 32
    
33.
Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, et al. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab 2007;293:E355-63.  Back to cited text no. 33
    
34.
Huang TH, Yang Q, Harada M, Uberai J, Radford J, Li GQ, et al. Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats: Modulation of cardiac PPAR-alpha-mediated transcription of fatty acid metabolicgenes. Toxicol Appl Pharmacol 2006;210:78-85.  Back to cited text no. 34
    
35.
Cornelius P, MacDougald OA, Lane MD. Regulation of adipocyte development. Annu Rev Nutr 1994;14:99-129.  Back to cited text no. 35
    
36.
Lefterova MI, Lazar MA. New developments in adipogenesis. Trends Endocrinol Metab 2009;20:107-14.  Back to cited text no. 36
    
37.
Kersten S. Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 2002;440:223-34.  Back to cited text no. 37
    
38.
Shimada T, Nagai E, Harasawa Y, Akase T, Aburada T, Iizuka S, et al. Metabolic disease prevention and suppression of fat accumulation by Salacia reticulata. J Nat Med 2010;64:266-74.  Back to cited text no. 38
    
39.
Ross SA, Gulve EA, Wang M. Chemistry and biochemistry of type 2 diabetes. Chem Rev 2004;104:1255-82.  Back to cited text no. 39
    
40.
Bennett WL, Odelola OA, Wilson LM, Bolen S, Selvaraj S, Robinson KA, et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: A systematic review. Ann Intern Med 2012;156(1 Pt 1):27-36.  Back to cited text no. 40
    
41.
Sheng H, Sun H. Synthesis, biology and clinical significance of pentacyclic triterpenes: A multi-target approach to prevention and treatment of metabolic and vascular diseases. Nat Prod Rep 2011;28:543-93.  Back to cited text no. 41
    
42.
Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, Schoonjans K, et al. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: Potential impact in diabetes. J Med Chem 2010;53:178-90.  Back to cited text no. 42
    
43.
Jung SH, Ha YJ, Shim EK, Choi SY, Jin JL, Yun-Choi HS, et al. Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activator. Biochem J 2007;403:243-50.  Back to cited text no. 43
    
44.
Wen X, Sun H, Liu J, Cheng K, Zhang P, Zhang L, et al. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: Synthesis, structure-activity relationships, and X-ray crystallographic studies. J Med Chem 2008;51:3540-54.  Back to cited text no. 44
    
45.
Chávez H, Estévez-Braun A, Ravelo AG, González AG. Friedelane triterpenoids from Maytenus macrocarpa. J Nat Prod 1998;61:82-5.  Back to cited text no. 45
    
46.
Huang TH, He L, Qin Q, Yang Q, Peng G, Harada M, et al. Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: Inhibition of cardiac expression of angiotensin II type 1 receptor. Diabetes Obes Metab 2008;10:574-85.  Back to cited text no. 46
    
47.
Hunyady L, Turu G. The role of the AT1 angiotensin receptor in cardiac hypertrophy: Angiotensin II receptor or stretch sensor? Trends Endocrinol Metab 2004;15:405-8.  Back to cited text no. 47
    
48.
Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004;63:423-32.  Back to cited text no. 48
    
49.
Ismail TS, Gopalakrishnan S, Begum VH, Elango V. Anti-inflammatory activity of Salacia oblonga Wall. and Azima tetracantha Lam. J Ethnopharmacol 1997;56:145-52.  Back to cited text no. 49
    
50.
Musini A, Rao MJ, Giri A. Phytochemical investigations and antibacterial activity of Salacia oblonga Wall ethanolic extract. Ann Phytomed 2013;2:102-7.  Back to cited text no. 50
    
51.
Palani S, Raja S, Kumar SN, Kumar BS. Nephroprotective and antioxidant activities of Salacia oblonga on acetaminophen-induced toxicity in rats. Nat Prod Res 2011;25:1876-80.  Back to cited text no. 51
    
52.
Singh NK, Biswas A, Rabbani SI, Devi K, Khanam S. Hyrdoalcoholic root bark extract of Salacia oblonga prevented mitomycin-C induced sperm abnormality in Wistar rats. Pharmacogn Mag 2009;5:254-9.  Back to cited text no. 52
    
53.
Chaudhuri S, Clement K, Heuer MA. Composition for Weight Loss Comprising Mulberry Leaf, Pinolenic Acid and Salacia oblonga Extract. Patent 20080241292; 2008.  Back to cited text no. 53
    
54.
Eskandari R, Jayakanthan K, Kuntz DA, Rose DR, Pinto BM. Synthesis of a biologically active isomer of kotalanol, a naturally occurring glucosidase inhibitor. Bioorg Med Chem 2010;18:2829-35.  Back to cited text no. 54
    
55.
Huang TH, Peng G, Li GQ, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: Activation of PPAR-alpha. Toxicol Appl Pharmacol 2006;210:225-35.  Back to cited text no. 55
    
56.
Wang J, Rong X, Li W, Yamahara J, Li Y. Salacia oblonga ameliorates hypertriglyceridemia and excessive ectopic fat accumulation in laying hens. J Ethnopharmacol 2012;142:221-7.  Back to cited text no. 56
    
57.
Liu L, Yang M, Lin X, Li Y, Liu C, Yang Y, et al. Modulation of hepatic sterol regulatory element-binding protein-1c-mediated gene expression contributes to Salacia oblonga root-elicited improvement of fructose-induced fatty liver in rats. J Ethnopharmacol 2013;150:1045-52.  Back to cited text no. 57
    
58.
Ardiles AE, González-Rodríguez A, Núñez MJ, Perestelo NR, Pardo V, Jiménez IA, et al. Studies of naturally occurring friedelane triterpenoids as insulin sensitizers in the treatment type 2 diabetes mellitus. Phytochemistry 2012;84:116-24.  Back to cited text no. 58
    
59.
Belcaro G, Cesarone M, Silvia E, Ledda A, Stuard S, Dougall M. Daily consumption of Reliv Glucaffect for 8 weeks significantly lowered blood glucose and body weight in 50 subjects. Phytother Res 2009;23:1673-7.  Back to cited text no. 59
    

 
   Authors Top


Priya Singh Kushwaha, is working as Project Fellow in Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, A Central University, Lucknow, India. She is mainly focused on separation of antidiabetic agents from natural origin.


Ashok K Singh, is pursuing Ph.D in Pharmaceutical Chemistry in Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, A Central University, Lucknow, India. He is concentrated on synthesis of organic compounds for hepatic carcinoma treatment.


Amit K Keshari, is currently working as Ph.D research scholar in Pharmaceutical Chemistry in Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, A Central University, Lucknow, India. His research is based on synthesis organic compounds for hepatic carcinoma treatment.


Siddhartha Maity, is currently working as Ph.D. student in Department of Pharmaceutical Technology, Jadavpur University, Kolkata. He is working on colon targeted drug delivery.


Sudipta Saha, is currently working as Assistant Professor in Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, A Central University, Lucknow, India. His research work is based on diabetes and hepatic/colon carcinoma both from natural and synthetic origin.



    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1]


This article has been cited by
1 Aspects of extraction and biological evaluation of naturally occurring sugar-mimicking sulfonium-ion and their synthetic analogues as potent a-glucosidase inhibitors from Salacia: a review
Priyanka Bagri,Karishma Chester,Washim Khan,Sayeed Ahmad
RSC Adv.. 2017; 7(45): 28152
[Pubmed] | [DOI]



 

Top
   
 
  Search
 
    Similar in PUBMED
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Clinical Trials
   Conclusion
    References
    Authors
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1127    
    Printed11    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    
    Cited by others 1    

Recommend this journal